D. Grasela

D. Gajjar, D. Grasela, C. Nord, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Garenoxacin pharmacokinetics in subjects with renal impairment*

S. Swan, Zaiqi Wang, D. Gajjar, 2007, Current medical research and opinion.

Nasogastric Administration of Garenoxacin as Crushed Tablets With and Without Concomitant Enteral Feeding in Healthy Subjects

Zaiqi Wang, D. Grasela, R. Vargas, 2007, Drugs in R&D.

Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

Thaddeus H. Grasela, Paul G. Ambrose, D. Grasela, 2001, Antimicrobial Agents and Chemotherapy.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)

N. Meanwell, R. Colonno, K. Yeung, 2012, Journal of medicinal chemistry.

Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food.

T. Shangguan, D. Grasela, S. Kaul, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

A. Lok, G. Everson, D. Grasela, 2011 .

Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

P. Tebas, J. Lemm, D. Grasela, 2014, Antimicrobial Agents and Chemotherapy.

Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

Min Gao, Anna Persson, D. Grasela, 2011, Hepatology.

Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C

W. Kraft, D. Grasela, A. Persson, 2012, Antimicrobial Agents and Chemotherapy.

Quantitative determination of BMS-378806 in human plasma and urine by high-performance liquid chromatography/tandem mass spectrometry.

D. Grasela, S. Unger, Y. Xue, 2007, Journal of separation science.

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.

Qi Gao, Min Gao, Steven Sheriff, 2017, Journal of medicinal chemistry.

In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043

D. Langley, L. Alexander, M. Krystal, 2010, Antimicrobial Agents and Chemotherapy.

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

T. Hassanein, P. Thuluvath, L. Webster, 2015, Journal of hepatology.

1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS

P. Marcellin, P. Thuluvath, G. Everson, 2013 .

Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.

J. Prieto, B. Sangro, T. Crocenzi, 2013 .

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

A. Lok, K. Reddy, T. Hassanein, 2013 .

Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients

D. Sica, D. Grasela, T. Gehr, 1991, European Journal of Clinical Pharmacology.

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants

D. Grasela, B. He, Naiyu Zheng, 2020, British journal of clinical pharmacology.

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

C. Coopersmith, R. Hotchkiss, G. Martin, 2019, Intensive Care Medicine.

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*

C. Coopersmith, R. Hotchkiss, G. Martin, 2019, Critical care medicine.

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

R. Parker, D. Haas, M. Noor, 2004, AIDS.

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects

Y. Yazdanpanah, F. Raffi, R. Bertz, 2013, Journal of acquired immune deficiency syndromes.

Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections

E. Ludwig, D. Gajjar, D. Grasela, 2004, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.

B. Cirincione, D. Grasela, P. Ambrose, 2007, Diagnostic microbiology and infectious disease.

Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients

G. Kearns, R. Jacobs, B. Cirincione, 2007, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Model for Gatiﬂoxacin in Pediatric Patients (cid:1)

G. Kearns, R. Jacobs, B. Cirincione, 2007 .

Effect of a High‐Fat Meal on the Pharmacokinetics of the Des‐F(6)‐Quinolone BMS‐284756

D. Gajjar, D. Grasela, A. Bello, 2002, Pharmacotherapy.

Model‐Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development

Marc Pfister, Jeffrey D Wetherington, Rajesh Krishna, 2010, Journal of clinical pharmacology.

Inhibition of carbamazepine metabolism by cimetidine.

D. Grasela, M. Rocci, 1984, Drug Metabolism And Disposition.

Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study

C. Pachai, A. Fura, P. Conaghan, 2023, The Lancet Rheumatology.

Deoxyspergualin: mechanism of action and pharmacokinetics.

S. Nadler, D. Grasela, E. Ramos, 1996, Transplantation proceedings.

The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease

K. Ataga, D. Grasela, E. Orringer, 2005, Journal of clinical pharmacology.

The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus

R. Bertz, D. Grasela, T. Eley, 2014, Clinical Drug Investigation.

Pharmacometrics and the Transition to Model‐Based Development

T H Grasela, T D Bjornsson, C W Dement, 2007, Clinical pharmacology and therapeutics.

Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

D. Grasela, A. Persson, T. Marbury, 2011, Hepatology.

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

P. Thuluvath, D. Grasela, M. Sulkowski, 2014, The New England journal of medicine.

Open‐Label, Nonrandomized Study of the Effects of Gatifloxacin on the Pharmacokinetics of Midazolam in Healthy Male Volunteers

F. LaCreta, G. Kollia, D. Grasela, 2000, Pharmacotherapy.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.

Pharmaceutics, Drug Delivery and Pharmaceutical Technology Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug

D. Grasela, P. Timmins, A. Dennis, 2013 .

Model‐Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry

Marc Pfister, Jeffrey D Wetherington, Rajesh Krishna, 2010, Journal of clinical pharmacology.